Mereo BioPharma Group plc (MAH0 F) stock market data APIs
€0.5423
0.05(9.2%)
as of January 16, 2026
Try our APIs with
free plan!
Mereo BioPharma Group plc Financial Data Overview
Price chart is built with
Anychart
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Prev. Close
0.5423
Open
0.5913
High
0.5967
Low
0.5347
52 wk Range
0.302-3.01
Market Cap
85 613 K
Shares Outstanding
159 M
Revenue
500 K
Beta
0.361
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mereo BioPharma Group plc data using free add-ons & libraries
Get Mereo BioPharma Group plc Fundamental Data
Mereo BioPharma Group plc Fundamental data includes:
- Net Revenue: 500 K
- EBITDA: -45 029 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mereo BioPharma Group plc News
New
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
Ultragenyx Pharmaceutical Inc. RARE incurred a loss of $2.25 per share in second-quarter 2023, wider than the Zacks Consensus Estimate of a loss of $2.11. The company reported a loss of $2.26 per shar...
Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
Ultragenyx Pharmaceutical Inc. RARE reported dosing the first group of patients in both its late-stage studies evaluating setrusumab (UX143) in young adults and pediatric patients with Osteogenesis Im...
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Ultragenyx Pharmaceutical Inc. Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximat...
Mereo BioPharma to Present at the Jefferies Healthcare Conference
Mereo BioPharma Group plc LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on r...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
